This morning, Biotalys released its H1 25 update, revealing: 1/ A cash position of EUR 15.7m, prioritizing progress in the U.S. and EU in regulatory review of EVOCA™, patent protection for EVOCA™ in upcoming markets and partnerships. 2/ Operating loss coming in at EUR -8.1m, with an increase (+27%) in R&D spending corresponding to EUR -6.5m.Biotalys approaches a pivotal moment with the regulatory decision on EVOCA™ in Q4 2025 as they continue to advance their AGROBODY™ platform.H1 25 results con ....
